Investigation of intrathecal transport of NPT002, a prospective therapeutic based on phage M13, in nonhuman primates
- 139 Downloads
Presently, there are no effective treatments for conditions characterized by protein misfolding, such as Alzheimer’s, Parkinson’s, and other diseases involving CNS. Since misfolding occurs at the earliest stage of the disease, it is likely to be involved in subsequent pathological developments. It has been found that NPT002 (bacteriophage M13) directly dissociates aggregates of misfolded proteins that form amyloid, including amyloid-β, tau and α-synuclein. For CNS applications, NPT002 requires delivery to the brain parenchyma, the target tissue. NPT002 is an elongated ~950 nm particle that cannot penetrate into the brain from the blood. Furthermore, phage particles, due to their size, cannot be effectively transported in vivo by diffusion. Considering the physiology of the leptomeningeal space, intrathecal administration appears to be a promising convection-driven avenue for NPT002 delivery. In this paper, we use positron emission tomography to investigate the transport of NPT002 in Macaca fascicularis. The data suggest that approximately 50 % of the administered dose can reach the cerebral leptomeningeal space after a single lumbar intrathecal injection. A biologically significant fraction of the phage then enters the brain, resulting in potentially therapeutic cortical and subcortical exposure.
KeywordsBacteriophage M13, NPT002, PET imaging Pharmacokinetics Brain Iodine-124
- 3.Gannon K, et al. NeuroPhage Pharmaceuticals, unpublished data on file. 2011–2012.Google Scholar
- 4.Gannon KS, Becker M, Lavie V, Tsubery H, Rockenstein E, Masliah E, et al. NPT001 targets Abeta, tau and alpha-synuclein aggregates in biochemical assays and in transgenic mouse models. Annual Meeting of Society for Neuroscience. Washington, DC; 2011.Google Scholar
- 5.Ksendzovsky A, Walbridge S, Saunders RC, Asthagiri AR, Heiss JD, Lonser RR. Convection-enhanced delivery of bacteriophage to the brain. J Neurosurg. 2012. doi:10.3171/.2012.4.jns111528.
- 6.Rennels ML, Gregory TF, Blaumanis OR, Fujimuto K, Grady PA. Evidence for a paravascular fluid circulation in the mammalian central nervous system, provided by rapid distribution of tracer protein throughout the brain from the subarachnoid spaces. Brain Res. 1985;326:47–63.PubMedCrossRefGoogle Scholar
- 7.Davson H, Segal MB. Physiology of the CSF and blood–brain barriers. Boca Raton: CRC Press; 1995.Google Scholar
- 12.Du Boulay GH, O’Connell J, Currie J, Bostick T, Verity P. Further investigation of pulsatile movements in the cerebrospinal fluid pathways. Acta Radiol. 1972;13:496–523.Google Scholar
- 17.Carney JPJ, Flynn JL, Cole KS, Fisher D, Schimel D, Via LE, et al. Preclinical PET/CT system for imaging non-human primates. IEEE Medical Imaging Conference. 2009; abstract M06-67.Google Scholar
- 19.Farris Griffith, editor. The rat in laboratory investigation. Philadelphia: Lippincott; 1949. p. 196–7.Google Scholar
- 21.Papisov M, Belov V, Fischman AJ, Belova E, Titus J, Gagne M. Delivery of proteins to CNS as seen and measured by positron emission tomography. Drug Deliv Trans Res. 2012 (in press).Google Scholar
- 22.Papisov M, Belov V, Fischman AJ, Bonab AA, Wiles M, Xie H, et al. PET imaging of enzyme pharmacokinetics in rats after IV and IT administration. Annual Meeting of SNM, Toronto, CA, June 2009.Google Scholar